Paclitaxel-induced Apoptosis May Occur without A Prior G 2/M-Phase Arrest

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 27-36

  Dziadyk, Jennifer M ^a   Sui, Meihua ^a   Zhu, Xueming ^a   Fan, Weimin ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apoptosis; I B ; Mitotic arrest; NF B; Paclitaxel

Indexed keywords

BACCATIN III; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PARTHENOLIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL DEATH; DEPOLYMERIZATION; DRUG EFFECT; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; G2 PHASE; HUMANS; I-KAPPA B PROTEINS; KB CELLS; MITOSIS; NF-KAPPA B; PACLITAXEL; SESQUITERPENES; SIGNAL TRANSDUCTION;

EID: 1442350558     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Holmes FA, Walter RS, Theriautt RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
2. Wani MC, Taylor HL, Wall ME et al: Plant antitumor agents: VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 23-25, 1971.
3. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB and Paietta E: Phase I clinical and pharmicokinetics study of taxol. Cancer Res 47: 2486-2493, 1987.
4. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 22: 665-667, 1979.
5. Kuman N: Taxol induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256: 10435-10441, 1981.
6. Rowinsky EK, Donehower RC, Jones RJ and Tucker RW: Microtubule changes and cytotoxicity in leukemia cell lines treated with taxol. Cancer Res 48: 4093-4100, 1988.
7. Horwitz SB: Mechanism of action of Taxol. Trends Pharmacol Sci 13: 134-136: 1992.
8. Manfredi JJ and Horwitz SB: Taxol: an antimitotic agent with a new mechanism of action. Pharmac Ther 25: 83-125, 1984.
9. Fuchs DA and Johnson RK: Cytologic evidence that Paclitaxel, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treatment Rept 62: 1219, 1978.
10. Bhalla K, Ibrado A, Tourhina E, Tang C, Mahonery ME and Huang Y: Paclitaxel induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7: 563-568, 1993.
11. Fan W, Everett ET, Tang C, Cooper T, Fang Q, Bhalla K and Norris JS: Glucocorticoid-mediated inhibition of Paclitaxel-induced apoptosis in leiomyosarcoma cells. Cell Pharm 1: 205-212, 1994.
12. Cheng L, Zheng S, Raghunathan K, Priest DG, Willingham MC, Norris JS and Fan W: Characterizations of Paclitaxel-induced apoptosis and altered gene expression in human breast cancer cells. Cell Pharm 2: 249-257, 1995.
13. Liu Y, Bhalla K, Hill C and Priest DG: Evidence for involvement of tyrosine phosphorylation in paclitaxel-induced apoptosis in human ovarian tumor cell line. Biochem Pharmacol 48: 1265-1272, 1995.
14. Huang Y, Johnson RK, Norris JS and Fan W: Nuclear factor-κ B/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60: 4426-4432, 2000.
15. Mcdaid HM and Horwitz SB: Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Phamacol 60: 908-918, 2001.
16. Okano J and Rustgi AK: Paclitaxel induces prolonged activation of Ra/MEK/ERK pathway independently of activation of programmed cell death machinery. J Biol Chem 22: 19555-19564, 2001.
17. Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556, 1993.
18. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H and Wilson L: Mitotic block induced in Hela cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825, 1996.
19. Torres KE and Horwitz SB: Mechanisms of paclitaxel-induced cell death are concentration dependent. Cancer Res 58: 3620-3626, 1998.
20. Lieu CH, Chang YN and Lai YK: Dual cytotoxic mechanisms of submicromolar Paclitaxel on human leukemia HL-60 cells. Biochem Pharmacol 53: 1587-1596, 1997.
21. Huang Y and Fan W: IκB kinase activation is involved in regulation of Paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharm 61: 105-113, 2002.
22. 2/M arrest. Cancer Chemother Pharmacol 44: 444-452, 1999.
23. Fan W, Cheng LR, Norris JS and Willingham MC: Glucocorticoids selectively inhibit Paclitaxel-induced apoptosis in a human breast cancer cell line. Cell Pharm 3: 435-440, 1996.
24. Fan W, Schandl CA, Cheng L, Norris JS and Willingham MC: Glucocorticoids modulate taxol cytotoxicity in human solid tumor cells. Cell Pharm 3: 343-348, 1996.
25. Huang Y, Fang Y, Dziadyk JM, Norris JS and Fan W: The possible correlation between activation of NF-κB/IκB pathway and the susceptibility of tumor cells to Paclitaxel-induced apoptosis. Oncol Res/Anti-Cancer Drug Design 13: 113-122, 2002.
26. Brown K, Park S, Kanno T, Franzoso G and Siebenlist U: Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκB-α. Proc Natl Acad Sci USA 90: 2532-2536, 1993.
27. Baldwin AS Jr: The NF-κB and IκB proteins: new discoveries and insights. Ann Rev Immunol 14: 649-683, 1996.
28. Baeuerle P and Baltimore D: Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor. Cell 53: 211-217, 1988.
29. Sun S, Elwood J and Greene WC: Both amino- and carboxyl-terminal sequences within IκBα regulate its inducible degradation. Mol Cell Biol 16: 1058-1065, 1995.
30. Barkett M and Gilmore TD: Control of apoptosis by Rel/NF-κB transcription factor. Oncogene 22: 6910-6924, 2000.
31. Kaltschmidt B, Kaltschmidt C, Hofmann TG, Hehner SP, Droge W and Schmit ML: The pro- or anti-apoptotic function of NF-κB is determined by the nature of apoptotic stimulus. Eur J Biochem 267: 3828-3835, 2000.
32. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
33. Bork PM, Schmitz ML, Kuhnt M, Escher C and Heinrich M: Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-κB. FEBS Lett 402: 85-90, 1997.
34. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Droge W and Schmitz ML: Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 273: 1288-1297, 1998.